When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Fluticasone furoate/umeclidinium bromide/vilanterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate/...

   The combination fluticasone furoate/umeclidinium bromide/vilanterol product is approved by the US Food and Drug Administration with an indication for the maintenance treatment of a chronic lung problem called chronic obstructive pulmonary disease (COPD) in adults who (1) have already tried fluticasone furoate/vilanterol (brand name Breo Ellipta) but are still experiencing symptoms of airway ...

3. GSK to cap out-of-pocket inhaler costs in US - AOL

   www.aol.com/news/gsk-cap-pocket-inhaler-costs...

   The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and Trelegy Ellipta, and would apply to patients ...

4. Analysis-Ozempic on Wall Street's list for 2027 ... - AOL

   www.aol.com/news/analysis-ozempic-wall-streets...

   Other possible 2027 candidates include Pfizer's cancer drugs Ibrance and Xtandi, GSK's asthma and chronic obstructive pulmonary disease (COPD) treatment Trelegy Ellipta, Teva's Huntington's ...

5. Ozempic, Trulicity among Medicare's priciest drugs, report finds

   www.aol.com/news/ozempic-trulicity-among-medic...

   AARP said five drugs that accounted for the largest share of Medicare spending included the diabetes drugs Trulicity and Ozempic, the asthma drug Trelegy Ellipta, the HIV medication Biktarvy and ...

6. Umeclidinium bromide - Wikipedia

   en.wikipedia.org/wiki/Umeclidinium_bromide

   Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol ) [ 4 ] [ 5 ] and also as a triple-therapy ...

7. Vilanterol - Wikipedia

   en.wikipedia.org/wiki/Vilanterol

   Vilanterol is an ultra-long-acting β 2-adrenoceptor agonist which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD). [1] [2] The combination is also approved for the treatment of asthma in Canada, Europe, Japan [3] and ...